Sometimes the market focuses heavily on short-term problems and misses the long-term potential of a business. That is where broker research can uncover interesting ASX opportunities.

While analysts can be wrong, their work can highlight businesses where the market may be underestimating future growth.

Three ASX shares that have recently caught my attention are named below.

ResMed Inc. (ASX: RMD)

The first ASX share I would consider buying is one where the market appears to have become much more cautious.

ResMed shares are trading around $31.44, and Morgans believes the recent weakness has created an attractive opportunity.

The concerns are understandable. Investors have been weighing the potential impact of GLP-1 therapies, the possibility of Philips returning to the US PAP market, and broader weakness across healthcare shares.

However, I think the bigger picture remains compelling. ResMed operates in a healthcare market with a huge long-term opportunity. Sleep apnoea and related breathing disorders affect a large number of people globally, and many remain undiagnosed or untreated. That creates a significant runway for growth.

I also like the direction of the business beyond traditional devices. Connected technology, digital health solutions, and software can help improve patient outcomes while making treatment more accessible.

Morgans highlighted that ResMed has de-rated to around 16 times forward earnings, close to its lowest valuation since the post-GFC period, while consensus still expects double-digit earnings growth. For this reason, it has a buy recommendation and $41.72 target price on its shares.

The risks are real, but I think the market may be underestimating the quality of the underlying business.

Flight Centre Travel Group Ltd (ASX: FLT)

The second opportunity comes from a business that has been caught up in broader travel uncertainty.

Flight Centre shares have struggled as investors assess the impact of geopolitical issues and weaker operating conditions.

But I think the long-term travel story remains attractive. People continue to value experiences, holidays, and international travel. When confidence improves, travel demand can recover quickly.

What interests me about Flight Centre is the strength of its position. The company has built a global travel network, strong brand recognition, and a valuable customer base. It also has a strong balance sheet.

Morgans believes the recent weakness creates an opportunity, highlighting the company’s financial strength and the potential for a stronger recovery in the second half of FY27. It has a buy recommendation and $14.80 target price on the shares.

I think the key is patience. The recovery may take time, but if travel conditions normalise, earnings and the share price could respond positively.

Sigma Healthcare Ltd (ASX: SIG)

The final ASX share I would look at is Chemist Warehouse owner Sigma Healthcare.

Ord Minnett believes the company’s UK expansion opportunity could become significant over time. The initial rollout is still small, but the market itself is large and fragmented, creating an opportunity for a proven retail model to expand.

What I find interesting is the possibility of taking existing capabilities into a new market. Sigma has access to pharmacy infrastructure, retail experience, and the backing of one of Australia’s strongest consumer brands through Chemist Warehouse.

There is execution risk, as with any international expansion. But I think the potential upside comes from the ability to replicate a successful model in a much larger market.

Ord Minnett recently placed a buy recommendation and $3.40 target price on the shares. I think this is a fair valuation and shows potential for good returns from its current share price of around $2.82.

Foolish takeaway

I think these three ASX shares are interesting because investors are currently looking beyond the headlines and asking whether the long-term opportunity has changed.

In my view, the businesses themselves still have attractive qualities. The challenge for investors is having the patience to wait for those strengths to become more visible.

The post Why I want to own these ASX shares brokers rate as buys appeared first on The Motley Fool Australia.

More reading

• How to tell if an ASX share is cheap or a value trap
• How should I invest my money in FY27?
• 2 ASX healthcare shares crashing, now bouncing: buy, hold or sell?
• Buy, hold, sell: Dexus, Resmed, BHP shares
• These are the 10 most shorted ASX shares

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Flight Centre Travel Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Yesterday, a2 Milk Co Ltd (ASX: A2M) released its FY26 results.

As Laura Stewart reported yesterday, the company reported preliminary FY26 results, featuring revenue up more than 12% to about $1.97 billion. 

This was despite China infant milk formula (IMF) sales declining due to supply chain disruptions.

Key results included: 

• FY26 revenue of approximately $1.97 billion, up over 12% year-over-year
• China label IMF sales down around 14% on FY25 after supply chain issues in 4Q26
• EBITDA margin expected at the high end of 14.0% to 14.5% guidance
• NPAT anticipated to be slightly up on FY25, with underlying NPAT also rising

Following the results, A2 Milk shares fell over 4%. 

What is Bell Potter’s updated outlook on A2 Milk shares?

Following the results, the team at Bell Potter provided updated guidance on A2 Milk shares. 

Bell Potter views the update as broadly positive, with revenue expected to land within guidance at $1.97 billion and EBITDA margins at the top end of the guided range, resulting in EBITDA of around $285 million, broadly in line with expectations. 

Profit guidance has improved, with NPAT now expected to be slightly higher year-on-year and operating cash conversion upgraded to around 70%, reflecting stronger cash generation than previously guided.

The key disappointment was the weaker-than-expected performance of China label infant formula, with revenue expected to decline 14% year-on-year and second-half sales falling more than 40% after adjusting for foreign exchange, significantly below Bell Potter’s forecasts. 

While product supply issues have largely been resolved and management is now focused on marketing initiatives to win back former customers and attract new users, Bell Potter believes the weakness suggests the company may need to rebalance its China sales mix in FY27.

As a result, Bell Potter has modestly increased its FY26 earnings forecast but reduced FY27 and FY28 estimates to reflect higher expected brand investment and a slower recovery in China. 

NPAT forecasts have been revised up 3% for FY26, but down 6% for FY27 and down 5% for FY28.

Hold recommendation maintained 

A2 Milk shares have experienced volatility in 2026, and are currently down nearly 20% year to date. 

Yesterday, A2 Milk shares closed at $7.37 per share. 

Bell Potter has maintained its hold recommendation and share price target of $6.90 on the company. 

This indicates a 6% downside from current levels. 

The post What is Bell Potter saying about A2 Milk shares after its results? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Wednesday
• A2 Milk shares jump again as China worries start to ease
• a2 Milk Company posts double digit FY26 revenue growth despite China supply setback
• Why this ASX financials stock is tipped to rebound 35% in the back half of 2026
• What is Bell Potter’s updated view on Telstra shares?

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It has been a tough 2026 so far for ASX 300 stock Elders Ltd (ASX: ELD). 

Elders is a leading supplier of fertiliser, agricultural chemicals and animal health products to rural and regional Australia. It has strong agency positions in livestock, wool and real estate.

Year to date, its share price has fallen 21%.

For comparison, the S&P/ASX 300 (ASX:XKO) index is up 0.5% in the same period. 

However after falling in 2026, the team at Bell Potter is optimistic it can recover in the next 12 months. 

Here is what’s behind the bullish view. 

Mixed conditions

Bell Potter notes that conditions for Elders have been mixed since the last reporting period. 

Strong livestock activity and significantly improved soil moisture across much of Australia’s cropping regions have been partly offset by lower crop input prices, particularly urea.

Livestock markets remained supportive during the third quarter, with higher cattle slaughter and yardings, stronger prices for cattle, lamb, mutton, and wool, and increased wool volumes, providing a positive backdrop for Elders’ agency business.

Cropping conditions have improved considerably after above-average rainfall across most of the Australian wheat belt, especially in southeastern Australia. 

Soil moisture and crop health indicators have strengthened to their highest positive deviation in the past 14 years, although drier conditions are still expected in the second half of 2026.

On the downside, crop input prices have continued to soften. 

Urea prices have fallen 47% from their peak and are now below pre-conflict levels, while glyphosate prices are down around 18%, which may reduce the value of Elders’ crop input sales despite benefiting farmers through lower costs.

Buy recommendation for ASX 300 stock 

Following share price weakness, the team at Bell Potter now views this ASX 300 stock as a buy-low candidate. 

Bell Potter has a buy recommendation along with a price target of $6.45 on the company. 

From yesterday’s closing price of $5.38, this indicates an upside potential of 20%. 

Our Buy rating unchanged. The market is pricing ELD for the effects of an El Nino, with the stock down -27% since the BOM announced the El Nino watch and the short interest >9%. 

While the intensity of El Nino is not anticipated until 2HCY26e, patterns over the major winter cropping selling window appear to have been broadly positive and livestock agency trends have remained favourable, to a degree derisking the FY26e outlook.

The post Is this ASX 300 stock a buy-low candidate after crashing 20% this year? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Elders confirms Killara Feedlot sale completion for June 2026
• 5 ASX dividend stocks for passive income investors

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Elders. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.